Agile Therapeutics, Inc.
AGRX
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 21.57M | 21.50M | 19.59M | 19.97M | 16.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.57M | 21.50M | 19.59M | 19.97M | 16.31M |
| Cost of Revenue | 7.84M | 8.66M | 8.98M | 8.44M | 7.39M |
| Gross Profit | 13.72M | 12.84M | 10.61M | 11.53M | 8.93M |
| SG&A Expenses | 25.49M | 26.82M | 28.28M | 31.72M | 32.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.12M | 37.43M | 39.48M | 42.69M | 42.61M |
| Operating Income | -13.56M | -15.94M | -19.89M | -22.71M | -26.30M |
| Income Before Tax | -15.86M | -7.79M | -14.47M | -13.93M | -19.06M |
| Income Tax Expenses | -- | -- | -- | 0.00 | 0.00 |
| Earnings from Continuing Operations | -15.86 | -7.79 | -14.47 | -13.93 | -19.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.86M | -7.79M | -14.47M | -13.93M | -19.06M |
| EBIT | -13.56M | -15.94M | -19.89M | -22.71M | -26.30M |
| EBITDA | -13.15M | -15.54M | -19.50M | -22.34M | -25.76M |
| EPS Basic | -3.23 | -3.65 | -9.84 | -13.10 | -20.84 |
| Normalized Basic EPS | -2.02 | -2.28 | -6.15 | -8.19 | -3.63 |
| EPS Diluted | -3.24 | -3.66 | -9.84 | -13.10 | -20.84 |
| Normalized Diluted EPS | -2.02 | -2.28 | -6.15 | -8.19 | -3.63 |
| Average Basic Shares Outstanding | 17.40M | 12.32M | 8.60M | 6.46M | 4.25M |
| Average Diluted Shares Outstanding | 17.40M | 12.32M | 8.60M | 6.46M | 4.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
